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Abstract: The cerebral cortex underlies our complex cognitive capabilities, yet we know little 
about the specific genetic loci influencing human cortical structure. To identify genetic variants 
impacting cortical structure, we conducted a genome-wide association meta-analysis of brain 
MRI data from 51,665 individuals. We analyzed the surface area and average thickness of the 
whole cortex and 34 regions with known functional specializations. We identified 199 significant 
loci and found significant enrichment for loci influencing total surface area within regulatory 
elements active during prenatal cortical development, supporting the radial unit hypothesis. Loci 
impacting regional surface area cluster near genes in Wnt signaling pathways, which influence 
progenitor expansion and areal identity. Variation in cortical structure is genetically correlated 
with cognitive function, Parkinson’s disease, insomnia, depression, neuroticism, and ADHD. 
One Sentence Summary: Common genetic variation is associated with inter-individual 
variation in the structure of the human cortex, both globally and within specific regions, and is 
shared with genetic risk factors for some neuropsychiatric disorders. 
Main Text: The human cerebral cortex is the outer grey matter layer of the brain, which is 
implicated in multiple aspects of higher cognitive function. Its distinct folding pattern is 
characterized by convex (gyral) and concave (sulcal) regions. Computational brain mapping 
approaches use the consistent folding patterns across individual cortices to label brain regions 
(1). During fetal development excitatory neurons, the predominant neuronal cell-type in the 
cortex, are generated from neural progenitor cells in the developing germinal zone (2). The radial 
unit hypothesis (3) posits that the expansion of cortical surface area (SA) is driven by the 
proliferation of these neural progenitor cells, whereas thickness (TH) is determined by the 
number of their neurogenic divisions. Variation in global and regional measures of cortical SA 
and TH have been reliably associated with neuropsychiatric disorders and psychological traits (4) 
(table S1). Twin and family-based brain imaging studies indicate that SA and TH measurements 
are highly heritable and are influenced by largely different genetic factors (5-7). Despite 
extensive studies of genes impacting cortical structure in model organisms, our current 
understanding of the genetic variation impacting human cortical size and patterning is limited to 
rare, highly penetrant variants (8, 9). These variants often disrupt cortical development, leading 
to altered postnatal structure. However, little is known about how common genetic variants 
impact human cortical SA and TH.  
 
To identify genetic loci associated with variation in the human cortex we conducted genome-
wide association meta-analyses of cortical SA and TH measures in 51,665 individuals from 60 
cohorts from around the world, who were primarily of European descent (~94%; tables S2–S4). 
Cortical measures were extracted from structural brain MRI scans in 34 regions defined by the 
commonly used Desikan-Killiany atlas, which establishes coarse partitions of the cortex. The 
regional boundaries are based on gyral anatomy labeled from between the depths of the sulci (10, 
11). We analyzed two global measures, total SA and average TH, and SA and TH for the 34 
regions averaged across both hemispheres, yielding 70 distinct phenotypes (Fig. 1A; table S1). 
 
Within each cohort genome-wide association (GWAS) for each of the 70 phenotypes was 
conducted using an additive model. To identify genetic influences specific to each region, the 
primary GWAS of regional measures included the global measure of SA or TH as a covariate. 
To estimate the multiple testing burden associated with analyzing 70 phenotypes we used matrix 
spectral decomposition (12), which yielded 60 independent traits, and a multiple-testing 
significance threshold of P ≤ 8.3 x 10-10. 
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The principal meta-analysis comprised results from 33,992 participants of European ancestry 
(23,909 from 49 cohorts participating in ENIGMA and 10,083 from the UK Biobank). We 
sought replication for loci reaching genome-wide significance (P ≤ 5 x 10-8) in an additional 
ENIGMA cohort (777 participants) and with the CHARGE consortium (13) (13,952 
participants). In addition, we meta-analyzed eight cohorts of non-European ancestry (2,944 
participants) to examine the generalization of these effects across ancestries. High genetic 
correlations were observed between the meta-analyzed ENIGMA European cohorts and the UK 
Biobank cohort using LD-score regression (total SA rG = 1.00, Z-score PrG = 2.7 x 10
-27, average 
TH rG = 0.91, Z-score PrG = 1.7 x 10
-19, indicating consistent genetic architecture between the 49 
ENIGMA cohorts and data collected from a single scanner at the primary UK Biobank imaging 
site.  
 
Across the 70 cortical phenotypes we identified 306 loci that were genome-wide significant in 
the principal meta-analysis (P ≤ 5 x 10-8; Fig. 1B; table S5). Of these, 118 have not been 
previously associated with either intracranial volume or cortical SA, TH, or volume (13-18). 
Twenty of these were insertions or deletions (INDELs). Eleven INDELs had a proxy single 
nucleotide polymorphism (SNP) available in the European replication data; no proxies were 
available for six INDELs and one SNP. Of the 299 loci for which the SNP or a proxy was 
available, 255 (SA: 241, TH: 14) remained genome-wide significant when the replication data 
were included in the meta-analysis, with 199 passing multiple testing correction (P ≤ 8.3 x 10-10; 
SA: 187, TH: 12). Of the 255 loci, 244 were available in the meta-analysis of non-European 
cohorts. The 95% confidence intervals around the non-European meta-analysis effect sizes 
included those from the European meta-analysis for 241 of these loci. Of the 244 loci available 
in the non-European cohorts, 189 had effects in the same direction in both the European and non-
European meta-analyses, and 111 became more significant when the whole sample was meta-
analyzed (table S5; fig. S1). Variability in effects across ancestry may be due to differences in 
allele frequency; however, the power for these comparisons is limited and further comparisons 
with larger non-European cohorts will help clarify the generalizability of these effects (table S5). 
We examined gene-based effects (allowing for a 50 kb window around genes), and found 
significant associations for 253 genes across the 70 cortical phenotypes (table S6). The meta-
analytic results are summarized as Manhattan, QQ, Forest, and LocusZoom plots (figs. S2–S5). 
 
Genetics of total SA and average TH 
Common variants explained 34% (SE = 3%) of the variation in total SA and 26% (SE = 2%) in 
average TH. These estimates account for more than a third of the heritability estimated from the 
QTIM twin sample (91% for total SA and 64% for average TH; table S7), indicating that more 
genetic variants, including rare variants, are yet to be identified. To examine the extent to which 
our results could predict SA and TH, we derived polygenic scores (PRS) from the principal 
meta-analysis results. These scores significantly predicted SA and TH in an independent sample 
of 5,095 European participants, explaining between 2–3% of the trait variance (given a PRS 
threshold of P ≤ 0.01 R2SA = 0.029, linear regression coefficient t-test P = 6.54 x 10-50; R2TH = 
0.022, t-test P = 3.34 x 10-33; table S8).  
 
We observed a significant negative genetic correlation between total SA and average TH (rG = -
0.32, SE = 0.05, Z-score PrG = 6.5 x 10
-12; Fig. 2A), which persisted after excluding the 
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chromosome 17 inversion region known to influence brain size (14) (rG = -0.31, SE = 0.05, Z-
score PrG = 3.3 x 10
-12). Genetic correlations could indicate causal relationships between traits, 
pleiotropy, or a genetic mediator influencing both traits. Latent causal variable (LCV) analysis, 
which tests for causality using genome-wide data (19), showed no evidence of causation (LCV 
genetic causality proportion gcp = 0.06, t-test Pgcp=0 = 0.729). The negative correlation suggests 
that genetic influences have opposing effects on SA and TH, which may result from pleiotropic 
effects or genetic effects on a mediating trait that, for example, might constrain total cortical 
volume. The absence of causality and the small magnitude of this correlation is consistent with 
the radial unit hypothesis (3), whereby different developmental mechanisms promote SA 
expansion and increases in TH. 
 
As expected, total SA showed a positive genetic correlation with intracranial volume (ICV); this 
correlation remained after controlling for height demonstrating that this relationship is not solely 
driven by body size (Fig. 2A; table S8). The global cortical measures did not show significant 
genetic correlations with the volumes of major subcortical structures (Fig. 2A) except for total 
SA and the hippocampus, consistent with their shared telencephalic developmental origin.  
 
To identify if common variation associated with cortical structure relate to gene regulation 
within a given tissue type, developmental time period, or cell-type, we performed partitioned 
heritability analyses (20) using sets of gene regulatory annotations from adult and fetal brain 
tissues (21, 22). Total SA and average TH showed the strongest enrichment of heritability within 
genomic regions of active gene regulation (promoters and enhancers) in brain tissue and in vitro 
neural models derived from stem cell differentiation (Fig. 2B; fig. S6A). To examine temporally 
specific regulatory elements, we selected those active regulatory elements specifically present in 
either mid-fetal brain or adult cortex. Total SA showed significant enrichment of heritability only 
within mid-fetal specific active regulatory elements, whereas average TH showed significant 
enrichment only within adult specific active regulatory elements (Fig. 2C, fig S6B). Stronger 
enrichment was found in regions of the fetal cortex with more accessible chromatin in the neural 
progenitor-enriched germinal zone than in the neuron-enriched cortical plate (fig. S6C), similar 
to a previous analysis for intracranial volume (21). We then performed an additional partitioned 
heritability enrichment analysis using regulatory elements associated with cell-type specific gene 
expression derived from a large single-cell RNA-seq study of the human fetal brain (23). This 
analysis revealed significant enrichment of total SA heritability in all progenitor cell-types 
including those in active phases of mitosis as well as three different classes of progenitor cells 
including outer radial glia cells, a cell-type associated with expansion of cortical surface area in 
human evolution (2) (Fig 2D, fig S6D). We also identified significant enrichments in upper layer 
excitatory neurons, oligodendrocyte progenitor cells, and microglia. These findings suggest that 
total SA is influenced by common genetic variants that may alter gene regulatory activity in 
neural progenitor cells during fetal development, supporting the radial unit hypothesis (3). In 
contrast, the strongest evidence of enrichment for average TH was found in active regulatory 
elements in the adult brain samples, which may reflect processes occurring after mid-fetal 
development, such as myelination, branching, or pruning (24). 
 
We conducted pathway analyses to determine if there was enrichment of association near genes 
in known biological pathways (25). We found 91 significant gene-sets for total SA and four for 
average TH (table S9). Gene-sets associated with total SA included chromatin binding, a process 
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guiding neurodevelopmental fate decisions (26) (table S9, fig. S7A). In addition, consistent with 
the partitioned heritability analyses implicating neural progenitor cells in total SA, gene ontology 
terms relevant to cell-cycle also showed significant enrichment in these analyses. 
 
Loci influencing total SA and average TH 
Seventeen of the 255 replicated loci were associated with total SA; 12 survived correction for 
multiple testing (Fig. 2E, table S5). Eight loci influencing total SA have been previously 
associated with ICV (14). These include rs79600142 (principal meta-analysis PMA = 2.3 x 10
-32; 
replication Prep = 3.5 x 10
-43; P-values reported from all meta-analytic results were for Z-scores 
from fixed-effect meta-analyses), in the highly pleiotropic chromosome 17q21.31 inversion 
region, which has been associated with Parkinson’s disease (27), educational attainment (28), 
and neuroticism (29). On 10q24.33, rs1628768 (Z-score PMA = 1.7 x 10
-13; Prep = 1.0 x 10
-17) was 
shown by our bioinformatic annotations (30) to be an expression quantitative trait locus (eQTL) 
influencing expression levels of the INA gene, and of the schizophrenia candidate genes (31) 
AS3MT, NT5C2 and WBP1L (linear regression coefficient t-test false discovery rate (FDR) 
corrected P-value for the association of rs1628768 with expression data from surrounding genes 
FDRCommonMind Consortium(CMC) < 1.0 x 10
-2; tables S11–S12). This region has been associated with 
schizophrenia, however, rs1628768 is in low linkage disequilibrium (LD) with the 
schizophrenia-associated SNP rs11191419 (r2 = 0.15; (32)). The 6q21 locus influencing total SA 
is intronic to FOXO3 (which also showed a significant gene-based association with total SA, 
table S6). The major allele of the lead variant rs2802295 is associated with larger total SA (Z-
score PMA = 2.5 x 10
-10; Prep = 2.5 x 10
-13) and is in complete LD with rs2490272, a SNP 
previously associated with higher general cognitive function (33). 
 
One locus not previously associated with ICV was rs11171739 (Z-score PMA = 8.4 x 10
-10; Prep = 
8.1 x 10-11) on 12q13.2. This SNP is in high LD with SNPs associated with educational 
attainment (28), and is an eQTL for RPS26 in fetal (34) and adult cortex (30)(t-test of Pearson’s r 
FDRFETAL = 2.0 x 10
-24, empirical t-test of Pearson’s r FDRGenotype-Tissue Expression(GTEx) = 3.3 x 10-40; 
tables S11–S12). On 3p24.1, rs12630663 (Z-score PMA = 1.3 x 10-8; Prep = 1.4 x 10-8) is of 
interest due to its proximity (~200kb) to EOMES (also known as TBR2), which is expressed 
specifically in intermediate progenitor cells in the developing fetal cortex (35). rs12630663 is 
located in a chromosomal region with chromatin accessibility specific to the germinal zone in the 
human fetal cortex (21). Putatively causal SNPs in this region (table S13) show significant 
chromatin interactions with the EOMES promoter (36). The region also contains numerous 
regulatory elements that when excised via CRISPR/Cas9 in differentiating neural progenitor 
cells significantly reduced EOMES expression (21). A rare homozygous chromosomal 
translocation in the region separating the regulatory elements from EOMES (fig. S8) silences 
EOMES expression and causes microcephaly (37), demonstrating that rare and common non-
coding variation can have similar phenotypic consequences, but to different degrees. 
 
The two replicated loci associated with average TH, neither of which have been previously 
identified, survived correction for multiple testing (Fig. 2E; table S5). On 3p22.1, rs533577 (Z-
score PMA = 8.4 x 10
-11; Prep = 3.7 x 10
-12) is a fetal cortex eQTL (t-test FDRFETAL= 1.8 x 10
-4) for 
RPSA, encoding a 40S ribosomal protein with a potential role as a laminin receptor (38). 
Laminins are major constituents of extracellular matrix, and have critical roles in neurogenesis, 
neuronal differentiation and migration (39). On 2q11.2, rs11692435 (Z-score PMA = 3.2 x 10
-10; 
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Prep = 4.5 x 10
-10) encodes a missense variant (p.A143V) predicted to impact ACTR1B protein 
function (40), and is an ACTR1B eQTL in fetal cortex (t-test FDRFETAL = 3.9 x 10
-2) (tables S11–
S12). ACTR1B is a subunit of the dynactin complex involved in microtubule remodeling, which 
is important for neuronal migration (41).  
 
Genetics of regional SA and TH 
The amount of phenotypic variance explained by common variants was higher for SA (8–31%) 
than TH (1–13%) for each of the specific cortical regions (Fig. 3A–B; table S7). To focus on 
region specific influences we controlled for global measures in the regional GWAS, which 
reduced the covariance between the regional measures (tables S14–S15). Similar to the genetic 
correlation between global SA and TH, when significant, genetic correlations between regional 
SA and TH within the same region were moderate and negative (tables S14–S15). This suggests 
that genetic variants contributing to the expansion of SA in a specific region tend to also 
contribute to thinner TH in that region.  
 
Genetic correlations between regions were calculated separately for SA and TH. Most genetic 
correlations between regions did not survive multiple testing correction. For SA significant 
positive genetic correlations were generally found between physically adjacent regions and 
negative correlations between more distal regions (Fig. 3A). This pattern mirrored the 
phenotypic correlations between regions and was also observed for TH (Fig. 3A–B). Consistent 
with this, hierarchical clustering of the genetic correlations resulted in a general grouping by 
physical proximity (fig. S9). These positive genetic correlations were strongest between SA of 
regions surrounding the major, early forming sulci (e.g., pericalcarine, lingual, cuneus, and 
lateral occipital regions surrounding the calcarine sulcus), which may potentially reflect genetic 
effects acting on the development of the sulci (11). 
 
To further investigate biological pathways influencing areal (regional) identity, we aggregated 
association statistics using multivariate GWAS analyses (42) separately for regional SA and TH. 
These analyses identify variants shared across regions and those within specific regions while 
accounting for the phenotypic correlations between regions. Pathway analyses of the multivariate 
SA results showed significant enrichment for 903 gene sets (table S10), many of which are 
involved in Wnt signaling, with the canonical Wnt signaling pathway showing the strongest 
enrichment (Z-score, P = 8.8 x 10-11). Wnt proteins regulate neural progenitor fate decisions (43, 
44) and are expressed in spatially specific manners influencing areal identity (45). Pathway 
analyses of the multivariate TH results did not yield any findings that survived multiple testing 
correction. 
 
Loci influencing regional SA and TH 
A total of 224 loci were nominally associated with regional SA and 12 with regional TH; of 
these 175 SA and 10 TH loci survived multiple testing correction (table S5). As shown in Fig. 
1B, most loci were associated with a single cortical region. Of the loci influencing regional 
measures, few were also associated with global measures. Those that were showed effects in the 
same direction, implying that the significant regional loci were not due to collider bias (46) (fig. 
S10). 
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The strongest regional association was observed on chromosome 15q14 with the precentral SA 
(rs1080066, Z-score PMA = 1.8 x 10
-137; Prep = 4.6 x 10
-189; variance explained = 1.03%; Fig. 4A). 
Across 11 traits we observed 41 independent significant associations from 18 LD blocks (r2 
threshold ≤ 0.02; see Fig. 4B, table S5). As we observed strong association with the SA of both 
pre- and post-central gyri (Fig. 4C), we localized the association within the central sulcus in 
5,993 unrelated individuals from the UK Biobank. The most significant association between 
rs1080066 and sulcal depth was observed around the pli de passage fronto-pariétal moyen 
(linear regression coefficient t-test P = 7.9 x 10-21), a region associated with hand fine-motor 
function in humans (47), which shows distinct depth patterns across different species of primates 
(48) (Fig. 4D). rs1080066 is a fetal cortex eQTL for a downstream gene EIF2AK4 (t-test 
FDRFETAL = 4.8 x 10
-2) encoding the GCN2 protein, which is a negative regulator of synaptic 
plasticity, memory and neuritogenesis (49). The functional data also highlight THBS1 via 
chromatin interaction between the rs1080066 region and the promoter in neural progenitor cells 
and an eQTL effect in whole blood (Z-score FDRBIOSgenelevel = 6.1 x 10
-6). THBS1 has roles in 
synaptogenesis and the maintenance of synaptic integrity (50). 
 
Consistent with enrichment in the pathway analyses, a number of other loci were located in 
regions with functional links to genes involved in Wnt signaling (fig. S7B), including 1p13.2, 
where rs2999158 (lingual SA, Z-score PMA = 1.9 x 10
-11, Prep = 3.0 x 10
-11; pericalcarine SA, Z-
score PMA = 1.9 x 10
-11; Prep = 9.9 x 10
-16) is an eQTL for ST7L and WNT2B (t-test FDRCMC < 1.0 
x 10-2) in adult cortex (tables S11–S12). On 14q23.1, we observed 20 significant loci (table S5) 
from four LD blocks. Our strongest association here was for the precuneus SA (rs73313052: Z-
score PMA = 1.1 x 10
-24; Prep = 2.2 x 10
-35). These loci are located near DACT1 and DAAM1, both 
involved in synapse formation and critical members of the Wnt signaling cascade (51, 52). 
rs73313052 and high LD proxies are eQTLs for DAAM1 (t-test FDRCMC < 1.0 x 10
-2) in adult 
cortex (tables S11–S12). 
 
Several of our regional associations occur near genes with known roles in brain development. 
For example, on chromosome 1p22.2, rs1413536 (associated with the inferior parietal SA: Z-
score PMA = 1.6 x 10
-10; Prep = 3.1 x 10
-14) is an eQTL in adult cortex for LMO4 (t-test FDRCMC < 
1.0 x 10-2), with chromatin interactions between the region housing both this SNP and 
rs59373415 (which is associated with the precuneus SA: Z-score PMA = 1.6 x 10
-10, Prep = 5.3 x 
10-12) and the LMO4 promoter in neural progenitor cells (table S11–S12). Lmo4 is one of the few 
genes already known to be involved in areal identity specification in the mammalian brain (53). 
 
Genetic relationships with other traits 
To examine shared genetic effects between cortical structure and other traits, we performed 
genetic correlation analyses with GWAS summary statistics from 23 selected traits. We observed 
significant positive genetic correlations between total SA and general cognitive function (54), 
educational attainment (28), and Parkinson’s disease (27), indicating that allelic influences 
resulting in larger total SA are in part shared with those influencing greater cognitive capabilities 
as well as an increased risk for Parkinson’s disease. For total SA, significant negative genetic 
correlations were detected with insomnia (55), attention deficit hyperactivity disorder (ADHD; 
56), depressive symptoms (57), major depressive disorder (58), and neuroticism (29) (Fig. 5A; 
table S16), again indicating that allelic influences resulting in smaller total SA are in part shared 
with those influencing an increased risk for these disorders and traits. To map the magnitude of 
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these effects across the brain, we calculated the genetic correlations across the cortical regions 
without correction for the global measures (Fig. 5B). Genetic correlations with average TH did 
not survive multiple testing correction, perhaps due to the weaker genetic associations detected 
in the TH analyses. At the regional level, significant genetic correlations were observed between 
precentral thickness and general cognitive function (rG = 0.27, Z-score PrG = 2.5 x 10
-5) and 
educational attainment (rG = 0.25, Z-score PrG = 4.0 x 10
-4) as well as between the inferior 
parietal thickness and educational attainment (rG = -0.19, Z-score PrG = 5.0 x 10
-4). To confirm 
these correlations were not driven by the presence of cases within the meta-analysis, genetic 
correlations were recalculated from a meta-analysis of GWAS from population-based cohorts 
and GWAS of controls from the case-control cohorts (N = 28,503). All genetic correlations 
remained significant with the exception of the genetic correlation between total SA and 
depressive symptoms (table S17).  
 
We performed bidirectional Mendelian randomization (MR; 59) and LCV (19) analyses to 
investigate potential causal relationships underlying the observed genetic correlations with total 
SA. Both methods provided evidence of a causal effect of total SA on general cognitive function 
(inverse variance weighted MR bMR-IVW = 0.15, SE = 0.01, Z-score P = 4.6 x 10
-8; LCV gcp = 
0.40, 95% CIs [0.23–0.57], t-test Pgcp=0 = 1.4 x 10-9) and educational attainment (bMR-IVW = 0.12, 
SE = 0.01, Z-score P = 2.1 x 10-21; gcp = 0.49, 95% CIs [0.26–0.72], t-test Pgcp=0 = 8.0 x 10-9) 
(table S18–S19). The MR analyses also indicated association in the reverse direction for both 
general cognitive function and education years (table S18); however, this was not supported by 
the LCV analyses (table S19). There was limited to no support for a causal relationship in either 
direction between total SA and the six other traits that showed significant genetic correlations 
(table S18–S19). Taken together these findings suggest that the previously reported phenotypic 
relationships between cortical surface area and general cognitive function (60, 61) may in part 
reflect underlying causal processes.  
 
Discussion 
Here we present a large-scale collaborative investigation of the effects of common genetic 
variation on human cortical structure using data from 51,665 individuals from 60 cohorts. 
Current knowledge of genes impacting cortical structure has been derived largely from creating 
mutations in model systems, such as the mouse, and observing impacts on brain structure (8). 
Given the differences between mouse and human cortical structures (62), this study provides an 
important genome-wide insight into human variation and genes impacting a characteristically 
human phenotype. Previous studies have identified rare variants that have large effects on 
cortical structure in humans (8), and this study adds to the catalog of the type of variation that 
impacts human cortical structure.  
 
We show that the genetic architecture of the cortex is highly polygenic and that variants often 
have a specific effect on individual cortical regions. This suggests that there are distinct genes 
involved in the development of specific cortical areas and raises the possibility of developmental 
and regional specificity in eQTL effects. We also find that rare variants and common variants in 
similar locations in the genome can lead to similar effects on brain structure, though to different 
degrees. For example, a balanced chromosomal translocation near EOMES leads to microcephaly 
in a region abutting a common variant signal associated with small changes in cortical surface 
area (fig. S8). 
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We provide evidence that genetic variation impacting gene regulation in progenitor cell-types, 
present in fetal development, impacts adult cortical surface area. This is consistent with the radial 
unit hypothesis, which states that an increase in proliferative divisions of neural progenitor cells 
leads to an expansion of the pool of progenitors resulting in increases in neuronal production and 
cortical surface area (3, 62). Notably, we see an enrichment of heritability in cortical surface area 
within regulatory elements that influence outer radial glia cells, this cell-type is considerably 
more prevalent in gyrencephalic species such as humans and has been hypothesized to account 
for the increased progenitor pool size in humans (2). 
 
We also find that Wnt signaling genes influence areal expansion in humans, as previously 
reported in model organisms such as mice (45). Cortical thickness was associated with loci near 
genes implicated in cell differentiation, migration, adhesion, and myelination. Consequently, 
molecular studies in the appropriate tissues, such as neural progenitor cells and their 
differentiated neurons, will be critical to map the involvement of specific genes.  
 
We demonstrate that genetic variation associated with brain structure also impacts general 
cognitive function, Parkinson’s disease, depression, neuroticism, ADHD, and insomnia. This 
implies that genetic variants impacting brain structure also impact brain function. While most of 
the structural differences in the cortex observed in these disorders have been reported for 
thickness, our results show significant genetic correlations in surface area. This might suggest 
the phenotypic differences observed in cortical thickness (table S1) partially reflect 
environmental influences, effects of illness or of treatment. We find evidence that brain structure 
is an important phenotype along the causal pathway leading from genetic variation to differences 
in general cognitive function and educational attainment. 
 
In summary, this work identifies genome-wide significant loci associated with cortical surface 
area and thickness and provides a deeper understanding of the genetic architecture of the human 
cerebral cortex and its patterning. 
 
Materials and Methods Summary: 
Participants 
Participants were genotyped individuals with cortical MRI data, from 60 cohorts. Participants in 
all cohorts in this study gave written informed consent and each site obtained approval from 
local research ethics committees or Institutional Review Boards. Ethics approval for the meta-
analysis was granted by the QIMR Berghofer Medical Research Institute Human Research Ethics 
Committee (approval: P2204). 
 
Imaging 
Measures of cortical SA and TH were derived from in vivo whole brain T1-weighted MRI scans 
using FreeSurfer MRI processing software (1). SA and TH were quantified for each subject 
across the whole cortex and within 34 distinct gyral-defined regions according to the Desikan-
Killiany atlas averaged across both hemispheres (10). 
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Genetic association analyses 
Within each cohort, GWAS were conducted on each of the 70 imaging phenotypes. After quality 
control, these data were meta-analyzed using METAL (63). Initially the GWAS from European 
cohorts were meta-analyzed together, yielding the principal results that were used in all 
subsequent analyses. We sought replication of the genome-wide significant loci with data from 
the CHARGE consortium. To examine generalization of effects, the GWAS from the non-
European cohorts were meta-analyzed together, and finally we meta-analyzed the European with 
the non-European results. Polygenic scores were derived from the principal meta-analysis and 
used to predict the amount of variance explained by the association of common genetic variants 
with the cortical SA and TH in an independent sample. 
 
SNP heritability and tests for genetic correlations and causation 
Heritability explained by common genetic variants (SNP heritability) was estimated using LD 
score regression (64). Genetic correlations between cortical regions were estimated using cross-
trait LD score regression (65). To examine genetic relationships with other traits, we estimated 
genetic correlations using cross-trait LD score regression; to determine if these correlations were 
causal we used Mendelian randomization (59) and latent causal variable analyses (19). 
 
Partitioned heritability 
Partitioned heritability analysis was used to estimate the percentage of heritability explained by 
annotated regions of the genome (66). Heritability enrichment was first estimated in active 
regulatory elements across tissues and cell types (21, 22). Secondly, heritability enrichment was 
estimated in mid-fetal specific active regulatory elements and adult cortext specific active 
regulatory elements. Thirdly, heritability enrichment was estimated in regulatory elements of 
cell-type specific genes in fetal brain (23). 
 
Functional follow-up 
The principal meta-analytic results were followed up with gene-based association analysis using 
MAGMA (67). A multivariate analysis of the regional association results was conducted using 
TATES (42). Pathway analyses were conducted on the global measures and the results from the 
multivariate analyses using DEPICT to identify enrichment of association in known genetic 
functional pathways (25). To identify putatively causal variants we performed fine-mapping with 
CAVIAR (68). Potential functional impact was investigated using FUMA (30), which annotates 
the SNP location, nearby enhancers or promoters, chromatin state, associated eQTLs, and the 
potential for functional effects through predicted effects. 
 
References and Notes: 
1. B. Fischl, FreeSurfer. Neuroimage 62, 774-781 (2012). 
2. J. H. Lui, D. V. Hansen, A. R. Kriegstein, Development and evolution of the human neocortex. Cell 146, 
18-36 (2011). 
3. P. Rakic, Specification of cerebral cortical areas. Science 241, 170-176 (1988). 
4. P. M. Thompson et al., ENIGMA and global neuroscience: a decade of large-scale studies of the brain in 
health and disease across more than 40 countries. . PsyArXiv,  (2019). 
5. M. S. Panizzon et al., Distinct genetic influences on cortical surface area and cortical thickness. Cereb 
Cortex 19, 2728-2735 (2009). 
6. A. M. Winkler et al., Cortical thickness or grey matter volume? The importance of selecting the phenotype 
for imaging genetics studies. Neuroimage 53, 1135-1146 (2010). 
   Final Submitted Manuscript 
22 
 
7. L. T. Strike et al., Genetic complexity of cortical structure: differences in genetic and environmental factors 
influencing cortical surface area and thickness. Cereb Cortex,  (2018). 
8. B. I. Bae, D. Jayaraman, C. A. Walsh, Genetic changes shaping the human brain. Dev Cell 32, 423-434 
(2015). 
9. D. W. Meechan, T. M. Maynard, E. S. Tucker, A. S. LaMantia, Three phases of DiGeorge/22q11 deletion 
syndrome pathogenesis during brain development: patterning, proliferation, and mitochondrial functions of 
22q11 genes. Int J Dev Neurosci 29, 283-294 (2011). 
10. R. S. Desikan et al., An automated labeling system for subdividing the human cerebral cortex on MRI 
scans into gyral based regions of interest. Neuroimage 31, 968-980 (2006). 
11. See supplementary materials. 
12. D. R. Nyholt, A simple correction for multiple testing for single-nucleotide polymorphisms in linkage 
disequilibrium with each other. Am J Hum Genet 74, 765-769 (2004). 
13. E. Hofer et al., Genetic determinants of cortical structure (thickness, surface area and volumes) among 
disease free adults in the CHARGE consortium. bioRxiv, 409649 (2019). 
14. H. H. Adams et al., Novel genetic loci underlying human intracranial volume identified through genome-
wide association. Nat Neurosci 19, 1569-1582 (2016). 
15. L. T. Elliott et al., Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature 
562, 210-216 (2018). 
16. M. A. Ikram et al., Common variants at 6q22 and 17q21 are associated with intracranial volume. Nat Genet 
44, 539-544 (2012). 
17. D. P. Hibar et al., Common genetic variants influence human subcortical brain structures. Nature 520, 224-
229 (2015). 
18. J. L. Stein et al., Identification of common variants associated with human hippocampal and intracranial 
volumes. Nat Genet 44, 552-561 (2012). 
19. L. J. O’Connor, A. L. Price, Distinguishing genetic correlation from causation across 52 diseases and 
complex traits. bioRxiv, 205435 (2017). 
20. H. K. Finucane et al., Heritability enrichment of specifically expressed genes identifies disease-relevant 
tissues and cell types. Nat Genet 50, 621-629 (2018). 
21. L. de la Torre-Ubieta et al., The dynamic landscape of open chromatin during human cortical neurogenesis. 
Cell 172, 289-304.e218 (2018). 
22. Roadmap Epigenomics Consortium et al., Integrative analysis of 111 reference human epigenomes. Nature 
518, 317-330 (2015). 
23. D. Polioudakis et al., A Single-Cell Transcriptomic Atlas of Human Neocortical Development during Mid-
gestation. Neuron 103, 785-801 e788 (2019). 
24. J. C. Silbereis, S. Pochareddy, Y. Zhu, M. Li, N. Sestan, The cellular and molecular landscapes of the 
developing human central nervous system. Neuron 89, 248-268 (2016). 
25. T. H. Pers et al., Biological interpretation of genome-wide association studies using predicted gene 
functions. Nat Commun 6, 5890 (2015). 
26. J. L. Ronan, W. Wu, G. R. Crabtree, From neural development to cognition: unexpected roles for 
chromatin. Nat Rev Genet 14, 347-359 (2013). 
27. M. A. Nalls et al., Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and 
improving estimates of heritable risk. bioRxiv, 388165 (2018). 
28. J. J. Lee et al., Gene discovery and polygenic prediction from a genome-wide association study of 
educational attainment in 1.1 million individuals. Nat Genet 50, 1112-1121 (2018). 
29. M. Nagel et al., Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals 
identifies novel genetic loci and pathways. Nat Genet 50, 920-927 (2018). 
30. K. Watanabe, E. Taskesen, A. van Bochoven, D. Posthuma, Functional mapping and annotation of genetic 
associations with FUMA. Nat Commun 8, 1826 (2017). 
31. R. R. R. Duarte et al., Genome-wide significant schizophrenia risk variation on chromosome 10q24 is 
associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain. Am J Med 
Genet B Neuropsychiatr Genet 171, 806-814 (2016). 
32. Schizophrenia Psychiatric Genome‐Wide Association Study Consortium, Biological insights from 108 
schizophrenia-associated genetic loci. Nature 511, 421-427 (2014). 
33. S. Sniekers et al., Genome-wide association meta-analysis of 78,308 individuals identifies new loci and 
genes influencing human intelligence. Nat Genet 49, 1107-1112 (2017). 
   Final Submitted Manuscript 
23 
 
34. H. E. O’Brien et al., Expression quantitative trait loci in the developing human brain and their enrichment 
in neuropsychiatric disorders. Genome Biology 19, 194 (2018). 
35. C. Englund et al., Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor 
cells, and postmitotic neurons in developing neocortex. J Neurosci 25, 247-251 (2005). 
36. H. Won et al., Chromosome conformation elucidates regulatory relationships in developing human brain. 
Nature 538, 523-527 (2016). 
37. L. Baala et al., Homozygous silencing of T-box transcription factor EOMES leads to microcephaly with 
polymicrogyria and corpus callosum agenesis. Nat Genet 39, 454-456 (2007). 
38. V. DiGiacomo, D. Meruelo, Looking into laminin receptor: critical discussion regarding the non-integrin 
37/67-kDa laminin receptor/RPSA protein. Biol Rev Camb Philos Soc 91, 288-310 (2016). 
39. V. Solozobova, N. Wyvekens, J. Pruszak, Lessons from the embryonic neural stem cell niche for neural 
lineage differentiation of pluripotent stem cells. Stem Cell Rev 8, 813-829 (2012). 
40. C. Chelala, A. Khan, N. R. Lemoine, SNPnexus: a web database for functional annotation of newly 
discovered and public domain single nucleotide polymorphisms. Bioinformatics 25, 655-661 (2009). 
41. Y. Itoh, A balancing Akt: How to fine-tune neuronal migration speed. Neurogenesis 3, e1256854 (2016). 
42. S. van der Sluis, D. Posthuma, C. V. Dolan, TATES: efficient multivariate genotype-phenotype analysis for 
genome-wide association studies. PLoS Genet 9, e1003235 (2013). 
43. A. Chenn, C. A. Walsh, Regulation of cerebral cortical size by control of cell cycle exit in neural 
precursors. Science 297, 365-369 (2002). 
44. R. N. Munji, Y. Choe, G. Li, J. A. Siegenthaler, S. J. Pleasure, Wnt signaling regulates neuronal 
differentiation of cortical intermediate progenitors. J Neurosci 31, 1676-1687 (2011). 
45. S. J. Harrison-Uy, S. J. Pleasure, Wnt signaling and forebrain development. CSH Perspect Biol 4, a008094 
(2012). 
46. H. Aschard, B. J. Vilhjalmsson, A. D. Joshi, A. L. Price, P. Kraft, Adjusting for heritable covariates can 
bias effect estimates in genome-wide association studies. Am J Hum Genet 96, 329-339 (2015). 
47. M. D. Cykowski et al., The central sulcus: an observer-independent characterization of sulcal landmarks 
and depth asymmetry. Cereb Cortex 18, 1999-2009 (2008). 
48. W. D. Hopkins et al., Evolution of the central sulcus morphology in primates. Brain Behav Evol 84, 19-30 
(2014). 
49. M. Roffe, G. N. Hajj, H. F. Azevedo, V. S. Alves, B. A. Castilho, IMPACT is a developmentally regulated 
protein in neurons that opposes the eukaryotic initiation factor 2alpha kinase GCN2 in the modulation of 
neurite outgrowth. J Biol Chem 288, 10860-10869 (2013). 
50. A. R. Jayakumar et al., Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment 
reduces the level of synaptic proteins: in vitro and in vivo studies. J Neurochem 131, 333-347 (2014). 
51. R. Habas, Y. Kato, X. He, Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a 
novel Formin homology protein Daam1. Cell 107, 843-854 (2001). 
52. N. D. Okerlund et al., Dact1 is a postsynaptic protein required for dendrite, spine, and excitatory synapse 
development in the mouse forebrain. J Neurosci 30, 4362-4368 (2010). 
53. Z. Huang et al., Transcription factor Lmo4 defines the shape of functional areas in developing cortices and 
regulates sensorimotor control. Dev Biol 327, 132-142 (2009). 
54. J. E. Savage et al., Genome-wide association meta-analysis in 269,867 individuals identifies new genetic 
and functional links to intelligence. Nat Genet 50, 912-919 (2018). 
55. P. R. Jansen et al., Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and 
functional pathways. Nat Genet 51, 394-403 (2019). 
56. D. Demontis et al., Discovery of the first genome-wide significant risk loci for attention 
deficit/hyperactivity disorder. Nat Genet 51, 63-75 (2019). 
57. A. Okbay et al., Genetic variants associated with subjective well-being, depressive symptoms, and 
neuroticism identified through genome-wide analyses. Nat Genet 48, 624-633 (2016). 
58. D. M. Howard et al., Genome-wide meta-analysis of depression identifies 102 independent variants and 
highlights the importance of the prefrontal brain regions. Nat Neurosci 22, 343-352 (2019). 
59. G. Hemani et al., The MR-Base platform supports systematic causal inference across the human phenome. 
Elife 7,  (2018). 
60. M. A. McDaniel, Big-brained people are smarter: A meta-analysis of the relationship between in vivo brain 
volume and intelligence. Intelligence 33, 337-346 (2005). 
61. E. Vuoksimaa et al., The Genetic Association Between Neocortical Volume and General Cognitive Ability 
Is Driven by Global Surface Area Rather Than Thickness. Cereb Cortex 25, 2127-2137 (2015). 
   Final Submitted Manuscript 
24 
 
62. P. Rakic, Evolution of the neocortex: a perspective from developmental biology. Nat Rev Neurosci 10, 724-
735 (2009). 
63. C. J. Willer, Y. Li, G. R. Abecasis, METAL: fast and efficient meta-analysis of genomewide association 
scans. Bioinformatics 26, 2190-2191 (2010). 
64. B. K. Bulik-Sullivan et al., LD Score regression distinguishes confounding from polygenicity in genome-
wide association studies. Nat Genet 47, 291-295 (2015). 
65. B. Bulik-Sullivan et al., An atlas of genetic correlations across human diseases and traits. Nat Genet 47, 
1236-1241 (2015). 
66. H. K. Finucane et al., Partitioning heritability by functional annotation using genome-wide association 
summary statistics. Nat Genet 47, 1228-1235 (2015). 
67. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set analysis of GWAS 
data. PLoS Comput Biol 11, e1004219 (2015). 
68. F. Hormozdiari, E. Kostem, E. Y. Kang, B. Pasaniuc, E. Eskin, Identifying causal variants at loci with 
multiple signals of association. Genetics 198, 497-508 (2014). 
69. The 1000 Genomes Project Consortium, A global reference for human genetic variation. Nature 526, 68 
(2015). 
70. S. McCarthy et al., A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48, 1279-
1283 (2016). 
71. S. Purcell et al., PLINK: a tool set for whole-genome association and population-based linkage analyses. 
Am J Hum Genet 81, 559-575 (2007). 
72. C. A. Rietveld et al., GWAS of 126,559 individuals identifies genetic variants associated with educational 
attainment. Science 340, 1467-1471 (2013). 
73. S. Boker et al., OpenMx: An Open Source Extended Structural Equation Modeling Framework. 
Psychometrika 76, 306-317 (2011). 
74. L. Scrucca, M. Fop, T. B. Murphy, A. E. Raftery, mclust 5: Clustering, Classification and Density 
Estimation Using Gaussian Finite Mixture Models. R j 8, 289-317 (2016). 
75. J. J. Tielbeek et al., Genome-wide association studies of a broad spectrum of antisocial behavior. JAMA 
Psychiatry 74, 1242-1250 (2017). 
76. J. Grove et al., Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 51, 
431-444 (2019). 
77. E. A. Stahl et al., Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat 
Genet 51, 793-803 (2019). 
78. L. Duncan et al., Significant locus and metabolic genetic correlations revealed in genome-wide association 
study of anorexia nervosa. Am J Psychiatry 174, 850-858 (2017). 
79. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD 
Collaborative Genetics Association Studies (OCGAS), Revealing the complex genetic architecture of 
obsessive-compulsive disorder using meta-analysis. Mol Psychiatry 23, 1181-1188 (2018). 
80. L. E. Duncan et al., Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex 
differences in heritability. Mol Psychiatry 23, 666-673 (2018). 
81. A. F. Pardinas et al., Common schizophrenia alleles are enriched in mutation-intolerant genes and in 
regions under strong background selection. Nat Genet 50, 381-389 (2018). 
82. T. Otowa et al., Meta-analysis of genome-wide association studies of anxiety disorders. Mol Psychiatry 21, 
1391-1399 (2016). 
83. I. Pappa et al., A genome-wide approach to children's aggressive behavior: The EAGLE consortium. Am J 
Med Genet B Neuropsychiatr Genet 171, 562-572 (2016). 
84. I. E. Jansen et al., Genome-wide meta-analysis identifies new loci and functional pathways influencing 
Alzheimer's disease risk. Nat Genet 51, 404-413 (2019). 
85. J. Gao et al., Genome-wide association study of loneliness demonstrates a role for common variation. 
Neuropsychopharmacol 42, 811-821 (2017). 
86. Tobacco and Genetics Consortium, Genome-wide meta-analyses identify multiple loci associated with 
smoking behavior. Nat Genet 42, 441-447 (2010). 
87. International League Against Epilepsy Consortium on Complex Epilepsies, Genetic determinants of 
common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 13, 893-903 
(2014). 
88. R. Ferrari et al., Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet 
Neurol 13, 686-699 (2014). 
   Final Submitted Manuscript 
25 
 
89. M. Verbanck, C. Y. Chen, B. Neale, R. Do, Detection of widespread horizontal pleiotropy in causal 
relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50, 
693-698 (2018). 
90. J. J. Lee, M. McGue, W. G. Iacono, A. M. Michael, C. F. Chabris, The causal influence of brain size on 
human intelligence: Evidence from within-family phenotypic associations and GWAS modeling. 
Intelligence 75, 48-58 (2019). 
91. H. F. Porter, P. F. O'Reilly, Multivariate simulation framework reveals performance of multi-trait GWAS 
methods. Sci Rep 7, 38837 (2017). 
92. M. Kircher et al., A general framework for estimating the relative pathogenicity of human genetic variants. 
Nat Genet 46, 310-315 (2014). 
93. A. P. Boyle et al., Annotation of functional variation in personal genomes using RegulomeDB. Genome 
Res 22, 1790-1797 (2012). 
94. The GTEx Consortium, Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: 
multitissue gene regulation in humans. Science 348, 648-660 (2015). 
95. A. Ramasamy et al., Genetic variability in the regulation of gene expression in ten regions of the human 
brain. Nat Neurosci 17, 1418-1428 (2014). 
96. M. Fromer et al., Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat 
Neurosci 19, 1442-1453 (2016). 
97. D. Wang et al., Comprehensive functional genomic resource and integrative model for the human brain. 
Science 362,  (2018). 
98. P. M. Giusti-Rodriguez, P. F. Sullivan, Using three-dimensional regulatory chromatin interactions from 
adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. bioRxiv, 
406330 (2019). 
99. D. V. Zhernakova et al., Identification of context-dependent expression quantitative trait loci in whole 
blood. Nat Genet 49, 139-145 (2017). 
100. L. D. Ward, M. Kellis, HaploReg: a resource for exploring chromatin states, conservation, and regulatory 
motif alterations within sets of genetically linked variants. Nucleic Acids Res 40, D930-934 (2012). 
101. M. Perrot, D. Riviere, J. F. Mangin, Cortical sulci recognition and spatial normalization. Med Image Anal 
15, 529-550 (2011). 
102. D. Riviere et al., Automatic recognition of cortical sulci of the human brain using a congregation of neural 
networks. Med Image Anal 6, 77-92 (2002). 
103. W. D. Hopkins, O. Coulon, J. Mangin, Observer-independent characterization of sulcal landmarks and 
depth asymmetry in the central sulcus of the chimpanzee brain. Neuroscience 171, 544-551 (2010). 
104. O. Coulon et al., Cortical localization via surface parameterization: a sulcus-based approach. Neuroimage 
31, 29-185 (2006). 
105. O. Coulon et al., Two new stable anatomical landmarks on the Central Sulcus: definition, automatic 
detection, and their relationship with primary motor functions of the hand. Conf Proc IEEE Eng Med Biol 
Soc 2011, 7795-7798 (2011). 
106. M. F. Glasser et al., A multi-modal parcellation of human cerebral cortex. Nature 536, 171 (2016). 
107. J. D. Power et al., Functional network organization of the human brain. Neuron 72, 665-678 (2011). 
108. B. T. T. Yeo et al., The organization of the human cerebral cortex estimated by intrinsic functional 
connectivity. Journal of neurophysiology 106, 1125-1165 (2011). 
109. G. W. Bruyn, Atlas of the cerebral sulci. Clin Neurol Neurosur 93, 93 (1991). 
Acknowledgments: We thank K. Courtney for making panel A and M. R. Glass for making 
panel C of the Research Article Summary figure. We thank all cohort participants for making 
this work possible. We thank the research support staff of all cohorts, including interviewers, 
computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, 
receptionists, nurses, carers, participating general practitioners, and pharmacists. In addition, 
ALSPAC are grateful to midwives for their help in recruiting the families who participated in the 
study and thank L. B. Clauss for help during the quality control process of the ALSPAC 
neuroimaging data. BETULA thank the Centre for Advanced Study at the Norwegian Academy 
of Science and Letters in Oslo for hosting collaborative projects and workshops between Norway 
and Sweden in 2011–2012 and acknowledge that the image analyses were performed on 
   Final Submitted Manuscript 
26 
 
resources provided by the Swedish National Infrastructure for Computing at HPC2N in Umeå. 
BONN thank (in alphabetical order) M. Bartling, U. Broicher, L. Ehrmantraut, A. Maaser, B. 
Mahlow, S. Mentges, K. Raczka, L. Schinabeck, and P. Trautner for their support and help. 
CARDIFF thank researchers within Cardiff University who contributed to the MBBrains panel. 
DNS thank the staff of the Laboratory of NeuroGenetics. FBIRN thank L. McMillan for overall 
study coordination and H. Mangalam, J. Farran, and A. Brenner for administering the University 
of California, Irvine High-Performance Computing cluster. GIG thank M. Keil, E. Diekhof, T. 
Melcher, and I. Henseler for assistance in data acquisition. IMpACT acknowledge that in this 
work samples from the Netherlands node of IMpACT were used and the work was carried out on 
the Dutch national e-infrastructure with the support of the SURF Cooperative. MCIC thank 
colleagues who served as mentors, advisors, and supporters during the inception and conduct of 
the study, including D. Goff, G. Kuperberg, J. Goldstein, M. Shenton, R. McCarley, S. Heckers, 
C. Wible, R. Mesholam-Gately, and M. Vangel, staff and clinicians at each site responsible for 
data acquisition including S. Wallace, A. Cousins, R. Mesholam-Gately, S. Stufflebeam, O. 
Freudenreich, D. Holt, L. Kunkel, F. Fleming, G. He, H. Johnson, R. Pierson, A. Caprihan, P. 
Somers, C. Portal, K. Norman, D. South, M. Doty, and H. Milner and the expert guidance on 
image and other types of data acquisition obtained from L. Friedman, S. Posse, J. Jovicich, and 
T. Wassink. MCIC also acknowledge the many research assistants, students and colleagues who 
assisted in data curation over the years since data acquisition was completed, including S. 
Wallace, C. Zyloney, K. Sawlani, J. Fries, A. Scott, D. Wood, R. Wang, W. Courtney, A. 
Guimaraes, L. Shenkman, M. Kendi, A. T. Karagulle Kendi, R. Muetzel, T. Biehl, and M. 
Schmidt. MIRECC thank the US military veterans who participated in this research. MPIP thank 
R. Schirmer, E. Schreiter, R. Borschke, I. Eidner, and A. Olynyik for supporting MR acquisition 
and data management, the staff of the Center of Applied Genotyping for generating the 
genotypes of the Munich Antidepressant Response Signature (MARS) cohort, D. P. Auer for 
initiating the RUD-MR substudy, E. Binder for supporting participation in ENIGMA, and 
GlaxoSmithKline for providing the genotypes of the Recurrent Unipolar Depression Case-
Control Sample. PAFIP acknowledge the IDIVAL Neuroimaging Unit for imaging acquirement 
and analysis and Valdecilla Biobank for its help in the technical execution of this work. PDNZ 
are grateful to their colleagues including M. MacAskill, D. Myall, L. Livingston, B. Young, and 
S. Grenfell, staff at the New Zealand Brain Research Institute and Pacific Radiology 
Christchurch for study co-ordination and image acquisition, and Ms A. Miller for DNA 
preparation and banking. QTIM thank the many research assistants, radiographers, and IT 
support staff for data acquisition and DNA sample preparation. SHIP are grateful to M. Stanke 
for the opportunity to use his Server Cluster for the SNP imputation as well as to H. Prokisch and 
T. Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-Trend cohort. 
Sydney MAS acknowledge the genome-wide genotyping was performed by the Ramaciotti 
Centre, University of New South Wales. Acknowledgements from CHARGE replication cohorts: 
Austrian Stroke Prevention Family /Austrian Stroke Prevention Family Study thank B. Reinhart 
for her long-term administrative commitment, E. Hofer for technical assistance in creating the 
DNA bank, Ing. J. Semmler and A. Harb for DNA sequencing and analyses by TaqMan assays, 
and I. Poelzl for supervising the quality management processes after ISO9001 at the biobanking 
and DNA analysis stages. Cardiovascular Health Study thank a full list of principal investigators 
and institutions that can be found at CHS-NHLBI.org. Framingham Heart Study (CHARGE) 
especially thank investigators and staff from the Neurology group for their contributions to data 
collection. The generation and management of GWAS genotype data for the Rotterdam Study 
   Final Submitted Manuscript 
27 
 
were executed by the Human Genotyping Facility of the Genetic Laboratory of the Department 
of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. Rotterdam Study thank P. Arp, 
M. Jhamai, M. Verkerk, L. Herrera, M. Peters, and C. Medina-Gomez for their help in creating 
the GWAS database, and K. Estrada, Y. Aulchenko, and C. Medina-Gomez for the creation and 
analysis of imputed data. Three-City Dijon thank A. Boland (CNG) for technical help in 
preparing the DNA samples for analyses. The investigators of the frontotemporal GWAS (Ferrari 
et al, 2014, Lancet Neurol, PMID 24943344), the consortia members, and their 
acknowledgments are listed in the Supplementary Materials. Funding: This study was supported 
by U54 EB020403 from the NIH Big Data to Knowledge (BD2K) Initiative, a cross-NIH 
partnership. Additional support was provided by R01 MH116147, R01 MH1161671, P41 
EB015922, RF1 AG051710, RF1 AG041915, R56 AG058854, R01 AG059874, R01 
MH117601, the Michael J. Fox Foundation (MJFF; 14848), the Kavli Foundation, and by 
National Health and Medical Research Council (NHMRC) Project Grant 1158127 (to S.E.M). 
S.E.M. was funded by an NHMRC Senior Research Fellowship (APP1103623). K.L.G. was 
supported by APP1173025. L.C.-C. was supported by a QIMR Berghofer Fellowship. J.L.S. was 
supported by R01MH118349 and R00MH102357. 1000BRAINS thank the Heinz Nixdorf 
Foundation (Germany) for their generous support of the Heinz Nixdorf Recall Study, which is 
also supported by the German Federal Ministry of Education and Science (BMBF; FKZ 
01EG940) and the German Research Foundation (DFG; ER 155/6-1). This work was further 
supported by the BMBF through the Integrated Network IntegraMent under the e:Med Program 
(01ZX1314A to S.Ci), and by the Swiss National Science Foundation (156791 to S.Ci). The 
Initiative and Networking Fund of the Helmholtz Association supported S.Ca, the European 
Research Council (ERC) under the European Union's Horizon 2020 research and innovation 
programme (H2020) supported S.Ci (Human Brain Project SGA1, 720270) and supported S.Ca 
and S.Ci (Human Brain Project SGA2, 785907). Alzheimer's Disease Neuroimaging Initiative 
(ADNI1 and ADNI2GO) was supported by NIH (U01 AG024904) and Department of Defense 
ADNI (W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging (NIA), the 
National Institute of Biomedical Imaging and Bioengineering, and through generous 
contributions from: AbbVie; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; 
Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; 
Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. 
Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; 
IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & 
Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., 
Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis 
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical 
Company; and Transition Therapeutics. The Canadian Institutes of Health Research provided 
funds to support ADNI clinical sites in Canada. Private sector contributions were facilitated by 
the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is 
the Northern California Institute for Research and Education, and the study was coordinated by 
the Alzheimer’s Therapeutic Research Institute at the University of Southern California. Samples 
used in this study were from the National Centralized Repository for Alzheimer's Disease and 
Related Dementias, which received government support under a cooperative agreement grant 
(U24 AG21886) awarded by the NIA. Support for data analysis was provided by NLM R01 
LM012535 and NIA R03 AG054936 (to K.N.). The UK Medical Research Council (MRC) and 
Wellcome (102215/2/13/2) and the University of Bristol provide core support for ALSPAC. A 
   Final Submitted Manuscript 
28 
 
comprehensive list of grants funding is available on the ALSPAC website 
(http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). ALSPAC 
neuroimaging data was specifically funded by RO1 MH085772 (to T.P.). GWAS data was 
generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and 
LabCorp (Laboratory Corporation of America) using support from 23andMe. Data and sample 
collection by the Australian Schizophrenia Research Bank (ASRB) was supported by the 
Australian NHMRC, the Pratt Foundation, Ramsay Health Care, and the Viertel Charitable 
Foundation. The ASRB were also supported by the Schizophrenia Research Institute (Australia), 
utilizing infrastructure funding from NSW Health and the Macquarie Group Foundation. DNA 
analysis was supported by the Neurobehavioral Genetics Unit, utilizing funding from NSW 
Health and the NHMRC Project Grants (1067137, 1147644, 1051672). M.C. was supported by 
an NHMRC Senior Research Fellowship (1121474). C.P. was supported by a NHMRC Senior 
Principal Research Fellowship (628386 and 1105825). BETULA was supported by a Wallenberg 
Scholar grant from the Knut and Alice Wallenberg Foundation and a grant from Torsten and 
Ragnar Söderbergs Foundation to L.N., HelseVest RHF (911554 to S.L.H.), grants from the 
Bergen Research Foundation and the University of Bergen to S.L.H., grants from the Dr Einar 
Martens Fund and the K.G. Jebsen Foundation to S.L.H. and V.M.S., the Research Council of 
Norway (177458/V 50 to T.E. and 204966/F 20 to L.T.W.). Nijmegen’s BIG resource is part of 
Cognomics, a joint initiative by researchers of the Donders Centre for Cognitive Neuroimaging, 
the Human Genetics and Cognitive Neuroscience departments of the Radboud University 
Medical Center, and the Max Planck Institute for Psycholinguistics (funded by the Max Planck 
Society). Support for the Cognomics Initiative, including phenotyping and genotyping of BIG 
cohorts, comes from funds of the participating departments and centres and from external 
national grants: the Biobanking and Biomolecular Resources Research Infrastructure 
(Netherlands) (BBMRI-NL), the Hersenstichting Nederland, and the Netherlands Organisation 
for Scientific Research (NWO), including the NWO Brain & Cognition Excellence Program 
(433-09-229) and the Vici Innovation Program (016-130-669 to B.F.). Additional support was 
received from the European Union's Seventh Framework Program (FP7) [602805 
(Aggressotype), 602450 (IMAGEMEND), and 278948 (TACTICS)], from H2020 [643051 
(MiND) and 667302 (CoCA)], and from the Innovative Medicines Initiative 2 Joint Undertaking 
(H2020/EFPIA) [115916 (PRISM)]. BONN was supported by the Frankfurt Institute for Risk 
Management and Regulation and B.W. was supported by a Heisenberg Grant of the DFG [WE 
4427 (3-2)]. BrainScale was supported by NWO (NWO 51.02.061 to H.E.H.P., NWO 51.02.062 
to D.I.B., NWO-NIHC Programs of excellence 433-09-220 to H.E.H.P., NWO-MagW 480-04-
004 to D.I.B., and NWO/SPI 56-464-14192 to D.I.B.), FP7 Ideas: European Research Council 
(ERC-230374 to D.I.B.), and Universiteit Utrecht (High Potential Grant to H.E.H.P.). CARDIFF 
genotyping was supported by the National Centre for Mental Health. T.M.L. is funded by a Sêr 
Cyrmu II Fellowship (East Wales European Regional Development Funds (PNU-80762-CU-14) 
at the Dementia Research Institute, Cardiff University. DNS received support from Duke 
University as well as NIH (R01DA033369 and R01DA031579). Work from the London cohort 
of EPIGEN was supported by research grants from the Wellcome Trust (084730 to S.M.S.), 
University College London (UCL)/University College London Hospitals (UCLH) National 
Institute for Health Research (NIHR) Biomedical Research Centre/Specialist Biomedical 
Research Centres (CBRC/SBRC) (114 to S.M.S.), the Comprehensive Local Research Network 
Flexibility and Sustainability Funding (CEL1300 to S.M.S.), The Big Lottery Fund, the Wolfson 
Trust, and the Epilepsy Society. This work was partly undertaken at UCLH/UCL, which received 
   Final Submitted Manuscript 
29 
 
a proportion of funding from the NIHR CBRC/SBRC. FBIRN was supported by the NIH 
National Center for Research Resources (NCRR) [NIH 1 U24 RR021992 (Function Biomedical 
Informatics Research Network), NIH 1 U24 RR025736-01 (Biomedical Informatics Research 
Network Coordinating Center)], the NIH National Center for Research Resources and the 
National Center for Advancing Translational Sciences (UL1 TR000153), and the NIH through 
5R01MH094524, and P20GM103472. This work was supported in part by a Merit Review 
Award I01CX000497 (J.M.F.) and a Senior Research Career Award (J.M.F.) from the United 
States Department of Veterans Affairs, Clinical Sciences Research and Development Service. 
FOR2107 was funded by the DFG (FOR2107 DA1151/5-1 and DA1151/5-2 to U.D.; JA1890/7-
1, JA1890/7-2 to A.J.; KI 588/14-1, KI 588/14-2 to T.K.; KR 3822/7-1, KR 3822/7-2 to A.K.; 
NO246/10-1, NO246/10-2 to M.M.N.). GOBS was supported by the National Institute of Mental 
Health MH0708143 (to D.C.G.), MH078111 (to J.Bl.), and MH083824 (to D.C.G. and J.Bl.). 
Brain Genomics Superstruct Project (GSP) was made possible by the resources provided through 
Shared Instrumentation Grants 1S10RR023043 and 1S10RR023401 and was supported by 
funding from the Simons Foundation (to R.L.B.), the Howard Hughes Medical Institute (to 
R.L.B.), NIMH grants R01-MH079799 (to J.W.S.), K24MH094614 (to J.W.S.), K01MH099232 
(to A.J.H.), and the Massachusetts General Hospital-University of Southern California Human 
Connectome Project (U54MH091665). HUBIN was supported by the Swedish Research Council 
(2006-2992, 2006-986, K2007-62X-15077-04-1, K2008-62P-20597-01-3, 2008-2167, 2008-
7573, K2010-62X-15078-07-2, K2012-61X-15078-09-3, 14266-01A,02-03, 2017-949), the 
regional agreement on medical training and clinical research between Stockholm County Council 
and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation, and the HUBIN 
project. HUNT-MRI was funded by the Liaison Committee between the Central Norway 
Regional Health Authority and the Norwegian University of Science and Technology, and the 
Norwegian National Advisory Unit for functional MRI. IMAGEN was supported by the 
European Union’s FP6 Integrated Project IMAGEN (LSHM-CT- 2007-037286), the H2020 ERC 
Advanced Grant STRATIFY (695313), ERANID (PR-ST-0416-10004), BRIDGET (JPND: 
MR/N027558/1), the FP7 projects IMAGEMEND (602450) and MATRICS (603016), the 
Innovative Medicine Initiative Project EU-AIMS (115300-2), the Medical Research Foundation 
and MRC (MR/R00465X/1), the MRC (MR/N000390/1), the Swedish Research Council 
FORMAS, the NIHR Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King’s College London, the BMBF (01GS08152, 01EV0711, eMED 
SysAlc01ZX1311A, Forschungsnetz AERIAL), and the DFG (SM 80/7-1, SM 80/7-2, SFB 
940/1). Further support was provided from: ANR (AF12-NEUR0008-01 – WM2NA, and ANR-
12-SAMA-0004), the Fondation de France, the Fondation pour la Recherche Médicale, the 
Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives 
(MILDECA), the Fondation pour la Recherche Médicale (DPA20140629802), the Fondation de 
l’Avenir, Paris Sud University IDEX 2012,the National Institutes of Health, Science Foundation 
Ireland (16/ERCD/3797), the NIH (RO1 MH085772-01A1). IMH was supported by the National 
Healthcare Group, Singapore (SIG/05004; SIG/05028) and the Singapore Bioimaging 
Consortium (RP C-009/2006) research grants awarded to K.S.; M.La. was supported by an 
National Medical Research Council Research Training Fellowship (MH095: 003/008-1014) and 
Singapore Ministry of Health National Medical Research Council Center Grant 
(NMRC/CG/004/2013). IMpACT was supported by the NWO (433-09-229) and the Vici 
Innovation Program (016-130-669 to B.F.). Additional support was received from the ERC under 
FP7 [602805 (Aggressotype), 602450 (IMAGEMEND), and 278948 (TACTICS)] as well as 
   Final Submitted Manuscript 
30 
 
from H2020 [643051 (MiND), 667302 (CoCA), and 728018 (Eat2beNICE)]. LBC1936 was 
supported by a Research into Ageing programme grant (to I.J.D.) and the Age UK-funded 
Disconnected Mind project (http://www.disconnectedmind.ed.ac.uk; to I.J.D. and J.M.W.), with 
additional funding from the UK MRC (Mr/M01311/1, G1001245/96077, G0701120/79365 to 
I.J.D., J.M.W. and M.E.B.). The whole genome association part of this study was funded by the 
Biotechnology and Biological Sciences Research Council (BBSRC; BB/F019394/1). J.M.W. is 
supported by the Scottish Funding Council through the SINAPSE Collaboration 
(http://www.sinapse.ac.uk). CCACE (MRC MR/K026992/1) is funded by the BBSRC and MRC. 
LIBD was supported by direct funding from the NIMH intramural research program of the NIH 
to the Weinberger Lab and by support from the Lieber Institute for Brain Development and the 
Maltz Research Laboratories. MCIC was supported primarily by the Department of Energy DE-
FG02-99ER62764 through its support of the Mind Research Network (MRN, formerly known as 
the MIND Institute) and the consortium as well as by the National Association for Research in 
Schizophrenia and Affective Disorders (NARSAD) Young Investigator Award (to S.Eh.), 
through the Blowitz-Ridgeway and Essel Foundations and a ZonMw TOP 91211021 (to T.Wh.), 
a DFG research fellowship (to S.Eh.), the MRN, the NIH through NCRR 5MO1-RR001066 
(MGH General Clinical Research Center), NIMH K08 MH068540, the Biomedical Informatics 
Research Network with NCRR Supplements to P41 RR14075 (MGH), M01 RR 01066 (MGH), 
NIBIB R01EB006841 (MRN), R01EB005846 (MRN), 2R01 EB000840 (MRN), 
1RC1MH089257 (MRN), as well as grant U24 RR021992. Meth-CT was supported by the 
Medical Research Council, South Africa. MIRECC was supported by NIMH (1R01MH111671) 
and the US Department of Veterans Affairs (VISN6 MIRECC). MooDS was supported by the 
BMBF grants [National Genome Research Network Plus (MooDS: Systematic Investigation of 
the Molecular Causes of Major Mood Disorders and Schizophrenia, 
http://www.ngfn.de/en/schizophrenie.html); e:Med Programme: Integrated Network IntegraMent 
(01ZX1314A to M.M.N.; 01ZX1614A to F.D. and M.M.N.)], and was supported by DFG (FOR 
1617) as well as Excellence Cluster (EXC 257). MPIP was supported by a grant of the 
Exzellenz-Stiftung of the Max Planck Society and by the BMBF National Genome Research 
Network (FKZ 01GS0481). MPRC was supported by the NIH (R01MH116948, R01MH112180, 
U01MH108148, UG3DA047685, 2R01EB015611, R01DA027680, R01MH085646, 
P50MH103222, U54 EB020403, and T32MH067533), NSF (IIS-1302755 and MRI-1531491), a 
State of Maryland contract (M00B6400091), and a Pfizer research grant. MÜNSTER was funded 
by the DFG (SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for 
Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). NCNG was 
supported by the Bergen Research Foundation, the University of Bergen, the Research Council 
of Norway [FUGE (151904 and 183327), Psykisk Helse (175345), RCN (154313/V50 to I.R. 
and 177458/V50 to T.E.)], Helse Sørøst RHF (2012086 to T.E.), and Dr Einar Martens Fund. 
NESDA obtained funding from the NWO (Geestkracht program10-000-1002); the Center for 
Medical Systems Biology (CSMB, NWO Genomics), BBMRI-NL, VU University’s Institutes 
for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, University 
Medical Center Groningen, Leiden University Medical Center, NIH (R01D0042157-01A, 
MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the 
genotyping and analyses were funded by the Genetic Association Information Network (GAIN) 
of the Foundation for the National Institutes of Health. Computing was supported by BiG Grid, 
the Dutch e-Science Grid, which is financially supported by NWO. The NeuroIMAGE study was 
supported by NIH Grant R01MH62873, NWO Large Investment Grant 1750102007010 (to 
   Final Submitted Manuscript 
31 
 
J.K.B.), ZonMW grant 60-60600-97-193, NWO grants 056-13-015 and 433-09-242, and 
matching grants from Radboud University Nijmegen Medical Center, University Medical Center 
Groningen and Accare, and Vrije Universiteit Amsterdam. Further support was received from the 
FP7 [278948 (TACTICS), 602450 (IMAGEMEND), 602805 (Aggressotype)], and H2020 
[667302 (CoCA) and 728018 (Eat2beNICE)]. Netherlands Twin Register (NTR) obtained 
funding from NWO and ZonMW grants (904-61-090, 985-10-002, 912-10-020, 904-61-193,480-
04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 
056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-
Groot 480-15-001/674), Center for Medical Systems Biology (CSMB, NWO Genomics), 
NBIC/BioAssist/RK (2008.024), BBMRI–NL (184.021.007 and 184.033.111); Spinozapremie 
(NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University 
Research Fellow grant to DIB; Amsterdam Public Health research institute (former EMGO+) , 
Neuroscience Amsterdam research institute (former NCA); the European Science Foundation 
(EU/QLRT-2001-01254), FP7 (FP7- HEALTH-F4-2007-2013: 01413 (ENGAGE) and 602768 
(ACTION)]; the ERC (ERC Advanced, 230374, ERC Starting grant 284167), Rutgers University 
Cell and DNA Repository (NIMH U24 MH068457-06), the NIH (R01D0042157-01A1, 
R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 
MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South 
Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association 
Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing 
was supported by NWO through 2018/EW/00408559, BiG Grid, the Dutch e-Science Grid and 
SURFSARA. OATS was supported by the Australian NHMRC/Australian Research Council 
Strategic Award (401162) and NHMRC Project Grant (1405325). The study was facilitated 
through Twins Research Australia, a national resource in part supported by a Centre for Research 
Excellence from the NHMRC. DNA was extracted by Genetic Repositories Australia (NHMRC 
Grant 401184). Genome-wide genotyping at the Diamantina Institute, University of Queensland, 
was partly funded by a CSIRO Flagship Collaboration Fund Grant. OSAKA was supported by 
AMED under JP18dm0307002, JP18dm0207006 (Brain/MINDS) and JSPS KAKENHI 
J16H05375. PAFIP was supported by the Instituto de Salud Carlos III (PI14/00639 and 
PI14/00918), MINECO (SAF2010-20840-C02-02 and SAF2013-46292-R) and Fundación 
Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). PDNZ was 
supported by the Health Research Council, the Neurological Foundation of New Zealand, 
Canterbury Medical Research Foundation, University of Otago Research Grant, and Jim and 
Mary Carney Charitable Trust (Whangarei, New Zealand). PING was supported by the National 
Institute on Drug Abuse (RC2DA029475) and the U.S. National Institute of Child Health and 
Human Development (R01HD061414). Parkinson's Progression Markers Initiative (PPMI), a 
public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research 
and funding partners, including AbbVie, Allegran, Avid Radiopharmaceuticals, Biogen Idec, 
BioLegend, Bristol-Meyers Squibb, Denali Therapeutics, GE Healthcare, Genentech, GSK-
GlaxoSmithKline, Eli Lilly & Co., F. Hoffman-La Roche Ltd., Lundbeck Pharmaceuticals, 
Merck and Company, MSD-Meso Scale Discovery, Pfizer, Piramal, Sanofi Genzyme, Servier, 
Takeda Pharmaceutical Company, TEVA Pharmaceutical Industries, UCB Pharma SA, and 
Golub Capital (http://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors/). QTIM was 
supported by the National Institute of Child Health and Human Development (R01 HD050735), 
National Institute of Biomedical Imaging and Bioengineering (Award 1U54EB020403-01, 
Subaward 56929223), and NHMRC (Project Grants 496682, 1009064 and Medical 
   Final Submitted Manuscript 
32 
 
Bioinformatics Genomics Proteomics Program 389891). SHIP is part of the Community 
Medicine Research net of the University of Greifswald, Germany, which is funded by the DFG 
(01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs, the Social Ministry of 
the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to 
Individualized Medicine (GANI_MED)’ funded by the DFG (03IS2061A). Whole-body MR 
imaging was supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the 
Federal State of Mecklenburg West Pomerania. Genome-wide data have been supported by the 
DFO (03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the 
Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of 
the Caché Campus program of the InterSystems GmbH. Sydney MAS was supported by the 
NHMRC/Australian Research Council Strategic Award (401162) and NHMRC Program Grants 
(350833, 568969). DNA was extracted by Genetic Repositories Australia (NHMRC Grant 
401184). SYS has been funded by the Canadian Institutes of Health Research and the Heart and 
Stroke Foundation of Canada. Computations were performed on the GPC supercomputer at the 
SciNet HPC Consortium. SciNet is funded by the Canada Foundation for Innovation under the 
auspices of Compute Canada; the Government of Ontario; Ontario Research Fund - Research 
Excellence, and the University of Toronto. TCD-NUIG included data from two sites. NUI 
Galway data collection was supported by the Health Research Board (HRA_POR/2011/100). 
Trinity College Dublin was supported by The Science Foundation Ireland Research Investigator 
project (12.IP.1359 to G.D.). TOP and TOP3T are part of TOP, which is supported by the 
Research Council of Norway (223273, 213837, 249711, 226971, 262656), the South East 
Norway Health Authority (2017-112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ-MED-008) 
and the FP7 [602450 (IMAGEMEND)]. UiO2016 and UiO2017 are part of TOP and 
STROKEMRI, which is supported by the Norwegian ExtraFoundation for Health and 
Rehabilitation (2015/FO5146), the Research Council of Norway (249795, 248238), and the 
South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073). The UMCU 
cohort consists of several independent studies, which were supported by ZonMw TOP 40-008-
12-98-13009, Geestkracht programme of the ZonMw (10-000-1001), the Stanley Medical 
Research Institute (Dr. Nolen), the Brain and Behavior Research Foundation (2013-2015 
NARSAD Independent Investigator grant 20244 to M.H.J.H.), NWO (2012-2017 VIDI grants 
452-11-014 to N.E.M.v.H. and 917-46-370 to H.E.H.P.), and ZonMw (908-02-123 to H.E.H.P.). 
UNICAMP was supported by FAPESP (São Paulo Research Foundation) 2013/07559-3: The 
Brazilian Institute of Neuroscience and Neurotechnology (BRAINN). The collection of the 
chimpanzee brain images were supported by the NIH (NS-42867, NS-73134, and NS-92988). 
The views expressed in this manuscript are those of the authors and do not necessarily represent 
the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or 
the U.S. Department of Health and Human Services. Infrastructure for the CHARGE Consortium 
is supported in part by the National Heart, Lung, and Blood Institute (NHLBI; HL105756) and 
for the neuroCHARGE phenotype working group through the NIA (AG033193). H.H.H.A. was 
supported by the Netherlands Organization for the Health Research and Development (ZonMw; 
916.19.151). Atherosclerosis Risk in Communities Study (ARIC) was a collaborative study 
supported by the NHLBI (HHSN268201100005C, HSN268201100006C, HSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, 
HHSN268201100011C, HHSN268201100012C, R01HL70825, R01HL087641, R01HL59367, 
and R01HL086694); the National Human Genome Research Institute (U01HG004402); and the 
NIH (HHSN268200625226C). Infrastructure was partly supported by UL1RR025005, a 
   Final Submitted Manuscript 
33 
 
component of the NIH and NIH Roadmap for Medical Research. This project was partially 
supported by NIH R01 grants HL084099 and NS087541 (to M.Fo.). Austrian Stroke Prevention 
Family/Austrian Stroke Prevention Family Study databank was supported by the Medical 
University of Graz and the Steiermärkische Krankenanstaltengesellschaft. The research reported 
in this article was funded by the Austrian Science Fund (PI904, P20545-P05 and P13180), the 
Austrian National Bank Anniversary Fund (P15435), and the Austrian Ministry of Science under 
the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND; 
www.jpnd.eu). Cardiovascular Health Study was supported by NHLBI (HHSN268201200036C, 
HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, 
N01HC85082, N01HC85083, N01HC85086, U01HL080295, R01HL087652, R01HL105756, 
R01HL103612, R01HL120393, and R01HL130114), with additional contribution from the 
National Institute of Neurological Disorders and Stroke. Additional support was provided 
through R01AG023629, R01AG15928, and R01AG033193 from the NIA. The provision of 
genotyping data was supported in part by the National Center for Advancing Translational 
Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and 
Kidney Disease Diabetes Research Center grant DK063491 to the Southern California Diabetes 
Endocrinology Research Center. The Erasmus Rucphen Family Study was supported by the 
Consortium for Systems Biology, within the framework of the Netherlands Genomics Initiative 
(NGI)/NWO. ERF as a part of EUROSPAN (European Special Populations Research Network) 
was supported by the European Commission’s 5th Framework Programme (FP5) (QLG2-CT-
2002-01254), the FP6 (018947; LSHG-CT-2006-01947), and the FP7 (HEALTH-F4-2007-
201413 and 602633). High-throughput analysis of the ERF data was supported by a joint grant 
from the Netherlands Organisation for Scientific Research and the Russian Foundation for Basic 
Research (NWO-RFBR 047.017.043). High throughput metabolomics measurements of the ERF 
study was supported by BBMRI-NL. The Framingham Heart Study was supported by the 
National Heart, Lung and Blood Institute's Framingham Heart Study (N01-HC-25195 and 
HHSN268201500001I) and its contract with Affymetrix, Inc. for genotyping services (N02-HL-
6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) 
funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston 
University School of Medicine and Boston Medical Center. This study was also supported by 
grants from the NIA (R01s AG033040, AG033193, AG054076, AG049607, AG008122, 
AG016495, and U01-AG049505) and the National Institute of Neurological Disorders and 
Stroke (R01-NS017950). C.Dec. is supported by the Alzheimer’s Disease Center (P30 AG 
010129). LIFE-Adult: LIFE-Adult is funded by the Leipzig Research Center for Civilization 
Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the 
University of Leipzig. LIFE is funded by means of the European Union, by the European 
Regional Development Fund and by funds of the Free State of Saxony within the framework of 
the excellence initiative. This work was also funded by the DFG (CRC 1052 “Obesity 
mechanisms” project A1) and by the Max Planck Society. The Rotterdam Study was funded by 
Erasmus Medical Center and Erasmus University, Rotterdam, ZonMw, the Research Institute for 
Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of 
Rotterdam. The GWAS datasets are supported by NWO Investments (175.010.2005.011, 911-
03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the 
Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the NGI/NWO 
Netherlands Consortium for Healthy Aging (050-060-810). This work was performed as part of 
   Final Submitted Manuscript 
34 
 
the CoSTREAM project (www.costream.eu) and received funding from H2020 (667375). Three-
City Dijon was conducted under a partnership agreement among the Institut National de la Santé 
et de la Recherche Médicale (INSERM), the University of Bordeaux, and Sanofi-Aventis. The 
Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C 
Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction 
Générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, 
Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of 
Research–INSERM Programme “Cohortes et collections de données biologiques”. S.Deb. 
received investigator-initiated research funding from the French National Research Agency 
(ANR) and from the Fondation Leducq. S.Deb. is supported by a starting grant from the 
European Research Council (SEGWAY), a grant from the Joint Programme of 
Neurodegenerative Disease research (BRIDGET), from H2020 (643417 and 640643), and by the 
Initiative of Excellence of Bordeaux University. This work was supported by the National 
Foundation for Alzheimer’s disease and related disorders, the Institut Pasteur de Lille, the labex 
DISTALZ and the Centre National de Génotypage. Vietnam Era Twin Study of Aging (VETSA) 
was supported by the US NIH VA San Diego Center of Excellence for Stress and Mental Health 
R00DA023549, DA-18673, NIA R01 AG018384, R01 AG018386, R01 AG022381, R01 
AG022982, R01 DA025109 05, R01 HD050735, K08 AG047903, R03 AG 046413, and R01 
HD050735-01A2. Author Contributions: †K.L.G. and N.J. contributed to this work as co-first 
authors. ‡J.N.P., L.C.-C., J.B., D.P.H., P.A.L., and F.P. contributed to this work as co-second 
authors. §J.L.S., P.M.T., and S.E.M. contributed to this work as co-last authors. #Consortium 
authors are listed in Supplementary Materials. *N.J., J.L.S., P.M.T., and S.E.M. are 
corresponding authors: S.E.M. Sarah.Medland@qimrberghofer.edu.au, P.M.T. pthomp@usc.edu, 
J.L.S. jason_stein@med.unc.edu, N.J. njahansh@usc.edu. Central Analysis and Coordination 
Group: C.R.K.C., D.P.H., F.P., J.Br., J.L.S., J.N.P., K.L.G., L.C.-C., L.C.P.Z., L.T.S., 
M.A.B.M., N.J., N.S., P.A.L., P.M.T., S.E.M, S.I.T. Manuscript Writing, Preparation and 
Revision: A.H.Z., D.P.H., J.Br., J.L.S., J.N.P., K.L.G., L.C.-C., N.J., P.A.L., P.M.T., S.E.M. 
Project Support: D.Ga., M.A.B.M., M.J., N.S., R.E., V.R., Y.G. Cohort Principal Investigator: 
A.A.V., A.C., A.H., A.J.F., A.J.H., A.K.H., A.M.D., A.M.-L., A.R.H., A.W.T., B.C.-F., B.F., 
B.Mo., B.S.P., B.W., B.W.J.H.P., C.A.H., C.Dep., C.F., C.M., C.M.L., C.P., D.Am., D.C.G., 
D.I.B., D.J.S., D.P., D.R.W., D.v.E., E.G.J., E.J.C.d.G., L.E.H., F.A.H., F.C., G.D., G.F., G.G.B., 
G.L.C., G.S., H.B., H.E.H.P., H.F., H.G.B., H.J.G., H.V., H.W., I.A., I.E.Som., I.J.D., I.M., 
J.B.J.K., J.Bl., J.C.Be., J.C.D.-A., J.K.B., J.-L.M., J.L.R., J.N.T., J.O., J.R.B., J.W.S., J.Z., 
K.L.M., K.S., L.M.R., L.N., L.R., L.T.W., M.E.B., M.H.J.H., M.J.C., M.J.W., M.K.M.A., M.R., 
N.D., N.J., N.J.A.v.d.W., O.A.A., O.G., P.G.S., P.J.H., P.K., P.M.T., P.S.S., P.T.M., R.A.M., 
R.A.O., R.H., R.J.S., R.L.B., R.L.G., R.S.K., S.Ca., S.Des., S.E.F., S.L.H., S.M.S., S.R., T.E., 
T.J.A., T.J.C.P., T.L.J., T.P., T.T.J.K., U.D., V.C., V.J.C., W.C., W.U.H., X.C., Z.P. Imaging 
Data Collection: A.B., A.d.B., A.F.M., A.J., A.J.H., A.K., A.K.H., A.L.G., A.M.D., A.N.H., 
A.P., A.R.H., A.R.K., A.U., B.A.M., B.-C.H., B.D., B.F., G.B.P., B.W., B.W.J.H.P., C.B., 
C.D.W., C.J., C.L.B., C.L.Y., C.M., C.P., C.R.J., C.S.Re., D.Am., D.C.G., D.Gr., D.H.M., D.J., 
D.J.H., D.J.V., D.M.C., D.P.O., D.R.W., D.S.O., D.T.-G., D.v.E., D.v.R., D.Z., E.A., E.B.Q., 
E.J.C.d.G., L.E.H., E.Sh., G.B.P., G.D., G.F., G.I.d.Z., G.L.C., G.R., G.S., H.V., H.Y., I.A., 
I.E.Som., J.A.T., J.E.C., J.E.N., J.K.B., J.-L.M., J.-L.M., J.L.R., J.M.F., J.M.W., J.N.T., J.R., 
J.T.V., K.D., K.K., K.L.M., K.O.L., K.S., L.M.R., L.R., L.T.W., M.B.H., M.E.B., M.Fu., 
M.H.J.H., M.Ho., M.-J.v.T., M.J.W., M.-L.P.M., N.E.M.v.H., N.F.H., N.H., N.J.A.v.d.W., 
N.K.H., N.O., O.G., P.A.G., P.E.R., P.G.S., P.K., P.N., P.S.S., R.A.O., R.B., R.H., R.L.B., 
   Final Submitted Manuscript 
35 
 
R.L.G., R.R., R.S.K., R.W., S.A., S.C.M., S.Ca., S.Er., S.Ko., S.M., S.M.S., T.G.M.v.E., T.R.M., 
T.Wh., T.W.M., U.D., U.S., V.C., V.J.C., V.S.M., W.D.H., W.H., W.W., X.C. Imaging Data 
Analysis: A.F.M., A.H.Z., A.J.H., A.J.S., A.L.G., A.M.D., A.R., A.R.K., A.S., A.Th., A.U., 
B.A.G., B.C.R., B.F., B.K., B.S.P., C.B., C.C.F., C.C.H., C.D.W., C.J., C.L.Y., C.R.K.C., 
C.S.Ro., D.Al., D.C.G., D.Gr., D.H., D.J., D.J.H., D.M.C., D.P.H., D.P.O., D.T.-G., D.v.d.M., 
D.v.E., D.v.R., D.Z., E.E.L.B., E.Sh., E.Sp., E.W., F.M.R., F.P., F.S., G.I.d.Z., G.R., H.J.G., I.A., 
I.E.Som., I.K.A., J.A.T., J.B.J.K., J.C.V.M., J.-L.M., J.L.R., J.L.S., J.M.W., J.R., J.Z., K.D., 
K.L.M., K.N., K.S., K.W., L.B.L., L.H., L.Sa., L.Sc., L.Sh., L.T.S., L.T.W., L.v.E., L.C.P.Z., 
M.A., M.A.H., M.B.H., M.C., M.E.B., M.Fu., M.Ho., M.J.G., M.-J.v.T., M.J.W., M.Ki., M.La., 
M.P.Z., M.W., N.E.M.v.H., N.F.H., N.J., N.O., N.T.D., O.G., P.G.S., P.K., P.M.T., P.N., R.B., 
R.K., R.L.G., R.M.B., R.R., S.A., S.Ca., S.Des., S.Eh., S.Er., S.F.F., S.I.T., S.Ka., S.Ke., S.L.R., 
S.M.C.d.Z., S.R.M., T.A., T.A.L., T.G., T.G.M.v.E., T.J., T.K., T.L.P., T.P.G., T.R.M., T.Wh., 
T.Wo., T.W.M., U.D., W.W., X.C., Y.Q., Z.Z. Genetic Data Collection: A.A.A., A.A.-K., 
A.d.B., A.J.F., A.J.H., A.J.S., A.K.H., A.M.D., A.P., A.R.H., A.R.K., B.-C.H., B.F., B.Mo., 
B.T.B., B.W., B.W.J.H.P., C.B., C.D.W., C.F., C.M., C.P., C.P.D., C.S.Re., D.C.G., D.H.M., 
D.R.W., D.W.M., D.Z., E.A., E.B.Q., E.G.J., E.J.C.d.G., L.E.H., F.D., F.M., F.R.T., G.D., 
G.E.D., G.F., G.H., G.L.C., G.S., H.V., H.Y., I.E.Som., I.L.-C., J.A.T., J.B.J.K., J.Bl., J.E.C., 
J.E.N., J.-J.H., J.J.L., J.K.B., J.-L.M., J.-L.M., J.L.R., J.M.F., J.Q.W., J.R., J.W.S., K.A.M., K.D., 
K.O.L., K.S., L.M.R., L.R., L.Sh., M.A.K., M.F.D., M.H.J.H., M.Ha., M.Ho., M.J.C., M.J.W., 
M.La., M.-L.P.M., M.M.N., M.N., N.A.K., N.E.M.v.H., N.G.M., N.J.A.v.d.W., N.K.H., N.O., 
O.G., P.A.T., P.H., P.K., P.R.S., P.S.S., R.A.O., R.C.G., R.H., R.L.B., R.R., R.Se., R.S.K., R.W., 
S.A., S.Ci., S.Dj., S.E.F., S.Eh., S.Er., S.H., S.L.H., S.M.S., T.G.M.v.E., T.J.A., T.K.d.A., 
T.L.P., T.W.M., U.D., V.C., V.J.C., V.M.S., X.C. Genetic Data Analysis: A.A.-K., A.J.F., 
A.J.H., A.J.S., A.M.D., A.R.K., A.Te., A.Th., B.C.-D., B.F., B.K., B.M.-M., B.P., B.S.P., 
B.T.B., C.C.F., C.D.W., C.L.V., C.S.Re., C.S.Ro., C.W., C.Y.S., D.C.G., D.K., D.P.H., 
D.v.d.M., D.v.E., E.G.J., L.E.H., E.V., E.W., F.M., H.-R.E., I.E.J., I.E.Som., I.E.Søn., I.L.-C., 
I.O.F., J.Bl., J.Br., J.F.P., J.H.V., J.-J.H., J.L.R., J.L.S., J.N.P., J.Q.W., J.R.A., J.S., J.W.C., 
J.W.S., K.E.T., K.L.G., K.N., L.C.-C., L.M.O.L., L.Sh., L.C.P.Z., M.A.A.A., M.B., M.E.G., 
M.Fu., M.Ha., M.I., M.J., M.J.C., M.J.W., M.Ki., M.Kl., M.Kn., M.La., M.Lu., M.M.J.v.D., 
N.A.G., N.G.M., N.J., N.J.A., N.K.H., N.M.-S., N.R.M., O.G., P.A.L., P.G.S., P.H., P.H.L., 
P.K., P.M.T., P.R.S., Q.C., R.A.O., R.M.B., R.R., R.Se., S.Da., S.Des., S.E.M., S.Eh., S.G., S.H., 
S.H.W., S.L.H., S.M.C.d.Z., S.N., S.R.M., T.A.L., T.G., T.G.M.v.E., T.J., T.K.d.A., T.M.L., 
W.R.R., Y.M., Y.W. CHARGE Study Design: B.Ma., C.Dec., C.L.S., E.H., G.V.R., H.H.H.A., 
H.J.G., J.C.Bi., L.L., M.A.I., M.Fo., O.L.L., Q.Y., R.Sc., S.Deb., S.S., T.H.M., T.P., V.G., 
W.T.L. Competing Interests: A.M.D. is a Founder of CorTechs Labs, Inc. and has received 
funding through a Research Agreement between General Electric Healthcare and the University 
of California, San Diego. The terms of these arrangements have been reviewed by and approved 
by the University of California, San Diego in accordance with its conflict of interest policies. 
B.F. has received educational speaking fees from Shire and Medice. B.W.J.H.P. has received 
(non-related) research funding from Boehringer Ingelheim and Janssen Research. C.D.W. is 
currently an employee of Biogen. C.R.J. consults for Lilly and serves on an independent data 
monitoring board for Roche but receives no personal compensation from any commercial entity. 
C.R.J. receives research support from NIH and the Alexander Family Alzheimer’s Disease 
Research Professorship of the Mayo Clinic. D.H.M. is a consultant for Boehringer Ingelheim, 
GW/Greenwhich Biosciences, and Aptinyx. D.J.S. has received research grants and/or 
consultancy honoraria from Lundbeck and Sun. D.P.H. is currently an employee of Genentech, 
   Final Submitted Manuscript 
36 
 
Inc. and was previously employed by Janssen R&D, LLC. H.B. is on the advisory board for 
Nutricia Australia. R.S.K. has consulted for Alkermes, Otsuka, Luye Pharma, and Sunovion, and 
has received speaker fees from Janssen-Cilag and Lundbeck. None of the other authors declare 
any competing financial interests. H.J.G. has received travel grants and speaker honoraria from 
Fresenius Medical Care, Neuraxpharm and Janssen Cilag. H.J.G. has received research funding 
from the German Research Foundation, the German Ministry of Education and Research, the 
DAMP Foundation, Fresenius Medical Care, the EU Joint Programme Neurodegenerative 
Disorders and the European Social Fund. L.E.H. has received or is planning to receive research 
funding or consulting fees from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, 
Heptares, Pfizer, Sound Pharma, Luye Pharma, Takeda, and Regeneron. N.H. is a stockholder of 
Siemens AG, Erlangen, Germany. R.B. has received travel grants and speaker honoraria from 
Bayer Healthcare AG. R.L.B. is a paid consultant for Roche. Data and Materials Availability: 
The meta-analytic results presented in this paper are available to download from the ENIGMA 
consortium webpage http://enigma.ini.usc.edu/research/download-enigma-gwas-results. Access 
to cohort data is available either through public repositories or directly from the cohort. Direct 
requests are required when informed consent or the approved study protocol does not permit 
deposition into a repository. Requests for data by qualified investigators are subject to scientific 
and ethical review, to ensure the data will be used for valid scientific research and to ensure 
compliance with confidentiality, consent, and data protection regulations. Some of the data are 
subject to MTA or DTA and specific details on how to access data for each cohort are available 
in table S20.  
Supplementary Materials: 
Materials and Methods 
Supplementary Text 
Consortium Authors 
Additional Cohort Information 
Supplementary Acknowledgements 
Figs. S1 to S11 
Tables S1 to S19 
References (70–108) 
Fig. 1. Regions of the human cortex and associated genetic loci. (A) The 34 cortical regions 
defined by the Desikan-Killiany atlas. (B) Ideogram of loci influencing cortical SA and TH. 
Fig. 2. Genetics of Global Measures. (A) Genetic correlations between global measures and 
selected traits (red indicates significant correlation, FDR < 0.05). (B) Partioned heritability 
enrichment in active regulatory elements across tissues and cell types. (C) Partioned heritability 
enrichment in temporally specific active regulatory elements. (D) Partioned heritability 
enrichment in regulatory elements of cell-type specific genes in fetal brain. (E) Manhattan plot 
of loci associated with total SA (top) and TH (bottom), green diamonds indicate lead SNP in the 
principal meta-analysis, black diamonds indicate change in P-value after replication, dashed 
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horizontal line is genome-wide significance, solid horizontal line is multiple-testing correction 
threshold. 
Fig 3. Genetic and Phenotypic Correlations Between Cortical Regions. (A) Surface Area. (B) 
Thickness. The regions are numbered according to the legend of Fig. 1A. The proportion of 
variance accounted for by common genetic variants is shown in the first column (h2SNP). 
Phenotypic correlations from the UK Biobank are in the upper triangle. Genetic correlations 
from the principal meta-analysis are in the lower triangle. Only significant correlations are 
shown. 
Fig 4. Genetics of Regional Measures. (A) Regional plot for rs1080066, including additional 
lead SNPs within the LD block and surrounding genes, chromatin interactions in neural 
progenitor cells, chromatin state in RoadMap brain tissues*, and BRAINSPAN candidate gene 
expression in brain tissue**. (B) Ideogram of 15q14, detailing the significant independent loci 
and cortical regions. (C) rs1080066 (G allele) association with SA of regions. (D) rs1080066 
association with central sulcus depth and depth of several primate species *TssA:Active 
Transcription Start Site (TSS); TssAFlnk:Flanking Active TSS; TxFlnk:Transcription at gene 5' 
and 3'; Tx:Strong transcription; TxWk:Weak transcription; EnhG:Genic enhancers; 
Enh:Enhancers; Het:Heterochromatin; TssBiv:Bivalent/Poised TSS; BivFlnk:Flanking Bivalent 
TSS/Enhancer; EnhBiv:Bivalent Enhancer; ReprPC:Repressed; PolyComb; ReprPCWk:Weak 
Repressed PolyComb; Quies:Quiescent/Low. **DFC:dorsolateral prefrontal cortex; 
VFC:ventrolateral prefrontal cortex; MFC:anterior cingulate cortex; OFC:orbital frontal cortex; 
M1C:primary motor cortex; M1C-S1C:primary motor-sensory cortex; PCx:parietal neocortex; 
S1C:primary somatosensory cortex; IPC:posteroventral parietal cortex; A1C:primary auditory 
cortex; TCx:temporal neocortex; STC:posterior superior temporal cortex; ITC:inferolateral 
temporal cortex; Ocx:occipital neocortex; V1C:primary visual cortex. 
Fig 5. Genetic correlations with neuropsychiatric and psychological traits. (A) Genetic 
correlations with total SA and average TH positive correlations are shown in red, while negative 
correlations are shown in blue. (B) Regional variation in the strength of genetic correlations 
between regional surface area (without correction for total surface area) and traits showing 
significant genetic correlations with total surface area. 
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